Pre Conference Bootcamp Day: Monday, July 29

Our basic biology bootcamp will navigate through the intricacies of gamma delta T cell functions, exploring both engineered and non-engineered cell therapies cells including antibodies, and combination therapies. From fundamentals to advanced concepts, this immersive and comprehensive program is designed to provide participants with an in-depth understanding of the basic biology of gamma delta T cells. Join us for a day of exploration and learning which will influence your future therapeutic designs and clinical strategy.

Exploring the Evolving Landscape of Gamma Delta Cells to Improve Future Clinical Trial Designs

9:00 am Clinical Review Session: Unveiling the Enigma: Exploring Past & Present Clinical Insights into Gamma Delta Cells

  • Jonathan Fisher Principal Investigator, University College London
  • Marta Barisa Senior Manager - Scientific Project and Research Fellow, University College London
  • Lawrence Lamb Chief Scientific Officer & Executive Vice President, IN8Bio

Synopsis

  • An extensive break down of past and present clinical trials that have mapped the field of gamma delta T cells. From here we are able to identify definitive reasoning behind successes and failures and how this will predict what the future of gamma delta T therapies will look like.
  • Delve into historical milestones and breakthroughs that have shaped our understanding of gamma delta cells in clinical contexts
  • Explore recent advancements and emerging trends in clinical research surrounding gamma delta cells, including their role in immunity and potential therapeutic applications
  • Engage in a dynamic exchange of ideas and experiences, fostering collaboration among attendees to chart the future directions of gamma delta cell research in clinical practice
  • This session will include presentations from each speaker along with extensive discussion times, encouraging a whole room collaboration

10:30 am Morning Break & Refreshments

11:30 am Roundtable Discussion: Promise, Perils and Progress when Publishing in Biotech

  • Michael Lotze Professor of Surgery, Immunology & Bioengineering, UPMC Hillman Cancer Center

Synopsis

We have come through a major difficult period in funding for imaginative biotech, especially in the cell and gene therapy area.

Although academics have been told to ‘publish or perish’, this is less clear in biotechnology.

• De-risking investment by having vetted science peer reviewed and published

• Formalizing reporting activities with suitable scientific controls allows the knowns and the unknowns to come to life

• Promoting a work culture that values the individual and groups and their contributions, realized in publication

Delving into the Mechanisms and Pathways Underpinning Gamma Delta T Cell Cytotoxicity

12:15 pm Epigenetic Reprogramming of Immune Cells: Suplexa Offers Orthogonal and Complementary Technology to Gamma Delta Cells

  • Frank Borriello Founder & Chief Executive Officer, Alloplex Biotherapeutics Inc.

Synopsis

  • SUPLEXA technology is applicable to lymphoid immune cells, conferring upon them a number of anti-tumor functions
  • First-generation autologous SUPLEXA cells tested in a first-in-human study demonstrates single-agent activity in multiple solid tumors
  • The technology is compatible with a variety of engineering approaches mediated by viral and mRNA vectors

1:00 pm Lunch

2:00 pm Immunotherapy, Surgery and γδ T cells

Synopsis

  • Pre-operative γδ T cell functionality in the hostile microenvironment of solid tumours and responses to neoadjuvant immune checkpoint blockade immunotherapy
  • Explore the distinct biology of γδ T cells facilitating tissue residence, post-operative graft reconstitution and cancer immunosurveillance
  • Developing novel strategies to reduce post-operative cancer recurrence targeting and employing γδ T cells

2:45 pm Round Table Discussion: Best Practices and Lessons Learned in Manufacturing Gamma Delta T Cells

Synopsis

  • Round Table Discussion: Best Practices and Lessons Learned in Manufacturing Gamma Delta T Cells
  • How to create a healthy relationship and the challenges associated with the CDMO during the early stages to streamline timelines
  • Challenges when manufacturing processes are transferred from one facility to another facility
  • Process tools and real time monitoring techniques to enhance understanding of the process and how to support continuous process improvements.

3:30 pm End of Biology Bootcamp Day